By Chris Wack
Nevro shares gained after the company said it expects to see fourth-quarter and full-year 2024 revenue higher than analysts' expectations.
The medical-device company's stock was up 16%, to $3.83, midday Monday.
Nevro said it expects to see quarterly earnings of $105 million to $106 million, compared with the $100.5 million analysts polled by FactSet are looking for.
For the full year, the company said it is looking for revenue of $408 million to $409 million, while analysts are forecasting revenue of $403.6 million.
Nevro said revenue is higher primarily due to the effect of greater-than-anticipated spinal cord stimulation device replacement procedures in the fourth quarter of 2024.
Cash, cash equivalents and short-term investments are expected to total $292.5 million as of Dec. 31, an increase of $15.5 million from Sept. 30.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 13, 2025 13:52 ET (18:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。